ACP operates within established pharmaceutical governance frameworks and maintains responsibility for nominated medicinal cannabis products supplied in Australia. As sponsor, ACP holds accountability for maintaining regulatory records, documentation integrity, and ongoing compliance obligations in accordance with Therapeutic Goods Administration (TGA) requirements.
Products manufactured or sponsored by ACP are supported by independent analytical testing. ACP works with accredited third-party laboratories, including Pharmalytics, to verify product specifications such as cannabinoid profile, microbiological compliance, heavy metals, and other required parameters. Analytical results are reviewed as part of the formal release process and maintained within regulatory documentation systems.
ACP conducts its operations within validated pharmaceutical facilities and documented procedures aligned with Good Manufacturing Practice (GMP) requirements. Activities are structured to ensure controlled supply, documented traceability, and regulatory accountability across the product lifecycle.